Previous 10 | Next 10 |
Energy stocks could be attractive but beware of the macro-economic shifts that may affect the performance. Diversify your portfolio with a mix of sectors. Some strategies can be volatile so know yourself first to manage your emotions. For further details see: The Best Of...
Merck acquires Acceleron for $180 per share in cash. Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV. Five9 and Zoom Video Communications mutually terminate their merger ...
NovoCure has developed and is commercializing a therapy for fast-growing and aggressive brain tumor using TTFields. Its product has reached maturity phase in core active markets, with an expansion in new geographies on the cards. The healthcare equipment play is investing heavily ...
With recent buyouts of Trillium Therapeutics and Forty Seven Inc. in the CD47 space, it's my belief that should ALX Oncology deliver on data it could be next. ALX's CD47 drug ALX148 (Evorpacept) has shown great early clinical evidence in a few studies, and the drug already has seen in...
Curis (NASDAQ: CRIS) , a small-cap cancer specialist, posted a healthy gain in August. The biotech's shares rose by 16.6% last month, according to data provided by S&P Global Market Intelligence . What sparked this double-digit move higher? Curis' shares appeared to be a...
Pfizer (NYSE: PFE) announced in August that it plans to acquire Trillium Therapeutics (NASDAQ: TRIL) for nearly $2.3 billion. In this Motley Fool Live video recorded on Aug. 25 , Motley Fool contributors Keith Speights and Brian Orelli discuss why investors shou...
Kudos to Pfizer (NYSE: PFE) for its decision to acquire Trillium Therapeutics (NASDAQ: TRIL) . The small biotech's cancer pipeline is a great fit for Pfizer. Trillium's candidates could begin contributing to Pfizer's growth in the second half of the decade, just when the big...
A COVID-19 vaccine manufacturer is preparing to expand its pipeline, as evidenced by the definitive agreement with a Canadian clinical-stage immuno-oncology company. Pfizer will acquire Trillium Therapeutics (TSX:TRIL) (NASDAQ:TRIL) for $2.26 billion — a 118% premium ...
Motley Fool investors may feel that they’ve missed the boat after last week. Trillium Therapeutics (TSX:TRIL) (NASDAQ:TRIL) announced that Big Pharma company Pfizer would be acquiring Trillium Therapeutics stock, sending shares jumping 188% in a single day! As...
M&A and SPAC activity are back on track. Two rumored deals materialize at significant premiums. Five active deals completed successfully. For further details see: Merger Arbitrage Mondays - Landmark Infrastructure Partners Acquired By Its General Partner At A Signifi...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that i...